INSIGHTS ON DRUG DEVELOPMENT

• How Adept Formulation Helps Overcome Manufacturability Challenges

  Initial development, scaleup, and tech transfer of complex multi-particulate drug systems requires meticulous planning to mitigate manufacturing risks.

• Using Residual DNA Quantification Data To De-Risk mAb Development

  Residual DNA quantitation offers more than impurity measurement. When used across process steps, it helps compare purification performance, identify risks early, and ensure assays remain reliable.

• Why DSC Testing Is A Critical Step In Developing Biosimilar Drugs

  Explore the importance of testing in the regulatory process and how tools like Differential Scanning Calorimetry (DSC) are helping to bring more biosimilars to patients in need.

• Producing Quality APIs At Scale

  Targeted process optimization transformed an early‑phase API with yield and impurity challenges into a scalable, high‑quality manufacturing process ready to support ongoing drug development.

• The Analytical Advantage Across The Development Lifecycle

  5/7/2026

  Integrated, regulatory‑ready analytics help accelerate development, strengthen submissions, and ensure consistent product quality throughout the pharmaceutical lifecycle.

• A Human-Relevant Model Of The Liver Sinusoid

  11/7/2024

  This organ-on-a-chip model minimizes drug absorption while maintaining the essential architecture. Explore the specifications of this product engineered to model the human liver.

• Working With Clients To Develop Manufacturing Processes

  7/23/2026

  Greg Buenger, Group Leader of Chemical Development at Cambrex Charles City, on what it actually looks like when R&D hands a process to the plant — chemists on the floor for the first batch, advising operators and troubleshooting in real time.

• How Solid-State Science Solves Your Toughest API Challenges

  6/3/2026

  Difficult small molecules demand more than standard purification strategies. See how combining solid-state expertise with advanced chromatographic modeling improves filtration, purity, and scalability.

• Automating High-Throughput Screens Using Patient-Derived Organoids

  3/17/2025

  Many oncology drugs fail in later development stages due to inadequate predictive models. Explore how 3D cell models, like patient-derived organoids, offer a promising solution in the drug development process.